In recent years, immunotherapy has revolutionized SCLC treatment (3, 9, 10), with PD-1/PD-L1 inhibitors, such as Atezolizumab and Durvalumab, showing benefits in first-line treatment of ES-SCLC, extending median OS beyond one year (11, 12) Despite these advancements, current clinical treatment for SCLC largely depends on disease stage and metastasis, with no established therapies specifically targeting the molecular subtypes. The gene discussed is CD274; the disease is small cell lung carcinoma.